Patient-reported outcomes with etanercept therapy in patients with plaque psoriasis who lost response to adalimumab - 11/08/17
Doi : 10.1016/j.jaad.2017.04.744
Le texte complet de cet article est disponible en PDF.
Kim A. Papp, MD, Probity Medical Research; Stephen Tyring, MD, University of Texas Health Science Center and Center for Clinical Studies; Bradley S. Stolshek, PharmD, Amgen Inc.; Kara Creamer Rice, MS, Amgen Inc.; David H. Collier, MD, Amgen Inc.; Greg Kricorian, MD, Amgen Inc.; Jan Iles, MD, Amgen Inc.; Arunan Kaliyaperumal, PhD, Amgen Inc.; Jerry Bagel, MD, Psoriasis Treatment Center of Central New Jersey
Le texte complet de cet article est disponible en PDF.| Commercial support: This study was sponsored by Immunex, a wholly owned subsidiary of Amgen Inc. and by Wyeth, which was acquired by Pfizer in October 2009. |
© 2017
Publié par Elsevier Masson SAS.
Vol 76 - N° 6S1
P. AB191 - juin 2017 Retour au numéro
Article précédent
- Patient-reported outcomes measure of psoriasis symptom and sign diary (PSSD): Validation and development of response criteria using data from a phase III clinical trial
- Patient-reported symptoms and signs in patients with moderate-severe plaque psoriasis treated with guselkumab or adalimumab: Results from VOYAGE 1, a phase III clinical trial
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?